Lentigen Corporation focuses upon developing Lentiviral vector (LV) gene delivery technology for a wide variety of applications in biotechnology and medicine. Lentigen designs, constructs and manufactures Lentiviral vectors for research and clinical applications.

Lentigen's mission is to apply its core competency in Lentiviral vector technology to develop therapeutics, vaccines, and to provide them to researchers as highly efficient gene delivery tools. The ability to deliver genes efficiently into mammalian cells has numerous uses in biotechnology and biomedicine, as shown below. Lentiviral vectors are the only gene delivery system that can accomplish both high, efficient and stable gene delivery to a wide variety of cell types, including dividing cells.

Lentigen is executing its business strategy mainly through collaborations and partnerships. Lentigen focuses upon the design, construction and manufacture of Lentiviral vectors, while working with its partners to develop, test and commercialize its products and services.

Lentigen has focused its internal proprietary efforts upon using its LentiMax™ Lentiviral vector platform to rapidly develop a low cost vaccine for pandemic and seasonal Influenza. The Company has several collaborative gene therapy programs with leading academic institutions that are being funded with government grants. The business model provides the company multiple opportunities for success on the upside, with its proprietary/collaborative therapeutic and vaccine products, and provides a pipeline of product opportunities for future development and commercialization.

For more information please contact Greg Feulner at 443.543.5318 or greg.feulner@lentigen.com.